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Bioresorbable ultrathin fibers have highly functional features which can, preserve drug efficacy, 
avoiding premature degradation, and control drug release rates over long periods of time. In 
parallel, it is known that Alzheimer’s Disease (AD) has been linked to impaired insulin signalling 
in the brain. Glucagon-like peptide 1 (GLP-1) analogues have beneficial effects on insulin 
release and possess great neuroprotective effectsproperties. Herein, we describe for the first 
time the incorporation of a GLP-1 analogue, Liraglutide, into poly (lactic acid) (PLA) ultrathin 
fibers with in situ gelatin capsules, in order to provide the controlled release of Liraglutide, 
improving neuroprotective properties. In this study, PLA, a bioresorbable polymer in which 
degradation products have neurogenesis characteristics, was electrospun and loaded with 
Liraglutide. Moreover, PLA/Liraglutide fibers were encapsulated with gelatin and were shown to 
have better properties than the non-encapsulated groups fibers towards thein terms of 
controlled release of Liraglutide, which was accomplished in the present study for up to 60 days. 
We observed that this biodevice was completely encapsulated with gelatin, which made the 
material more hydrophilic than PLA fibers alone and the biodevice was able to enhance 
fibroblast interaction and reduce mitochondrial stress in a neuroblastoma cell line. In this 
manner, this study introduces a new material which can improve neuroprotective properties 
from AD oxidative stress via the sustained long-lasting release of Liraglutide to a neuroblastoma 
cell line.  
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Nano and ultrathin fibers have been considered essential promising candidates for 
numerous drug delivery systems 
1-3
. For the treatment ofFocused on brain pathology, polymeric 
fiber, based drug controlled systems have promising properties due to their ability to release 
drugs into circulation over long time periods, providing for time-dependent mechanical 
properties and modulating the release of bioactive agents 
4
.  Such properties have led to 
 
 
consequentially (what do you mean by this?) favorable efective drug bioresorbable delivery 
across the blood brain barrier (BBB) 
5, 6
, protecting its interaction (of what?) from within the brain 
7
.  Besides, the use of poly (lactic acid) (PLA) fibers in the brain has recently demonstrated 
neurogenesis and vascularization of damaged brain tissue 
8
. It is further known that self-
assembling nanofibers have potential for being useful in Alzheimer’s Disease (AD) therapy 
9, 10
. 
Concerning AD, Type 2 Diabetes Mellitus (T2DM) is considered a risk factor for this 
dementia type 
11, 12
. In the brain, insulin deficiency plays an important role in the process of 
synaptic loss and cognitive reduction 
13
, thus, affecting cellular metabolism, gene expression 
and neuronal repair systems 
14
.  
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone that potentiates 
insulin secretion, administered to patients with T2DM 
15
. An important advantage of GLP-1 and 
its analogues, such as Liraglutide, is that they do not affect blood glucose levels of normal 
glycaemic organisms 
16
. Furthermore, GLP-1 receptors are expressed by neurons 
17
 and have 
longer biological half-lives in the organism (the receptors?) 
18
. They are also capable of crossing 
the BBB, inducing neurogenesis, providing beneficial effects and delaying ageing of the brain 
19
.  
Consequently, the stimulation of the GLP-1 receptor represents a promising technique 
to improve impaired brain function in patients with AD 
20, 21
. For this, ultrathin fibers containing 
GLP-1 analogues may potentiate the therapeutic effects of this peptide for AD, especially 
because the peptide might be maintained in at constant circulation,concentrations over a long 
time period, continually reaching the BBB, improving drug performance in the brain. In the 
literature there appears to be no in vitro and/or in vivo studies that researched the association of 
ultrathin fibers with the aforementioned therapy for AD. 
Promisingly, in this study we incorporated a Liraglutide commercial analogue (Victoza
®
) 
into bioresorbable ultrathin PLA fibers encapsulated with gelatin, creating a biodevice able to 
provide sustained and long-lasting release of the drug for AD treatment. The developed 
materials were further characterized and tested in vitro. Again, this therapy is very 
attractivepromising, once if the biodevice provides Liraglutide sustained release of Liraglutide, 
combining advantages of the drug with suitable mechanical properties, bioactive surfaces and 
controllable degradability of the materials. Importantly, our biodevice was non-toxic to 
fibroblasts and able to release ~100nM (do you mean nmol? nM is a concentration) of 
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Liraglutide per day, improving neuroblastoma viability for 1, 2 and 7 days reducing mitochondrial 







 2003D) was purchased from NatureWorks. The solvents used in this study 
were N,N-dimethylformamide (DMF, Sigma-Aldrich, ≥ 99%) and chloroform (Sigma-Adrich, ≥ 
99%). Liraglutide was purchased from Novo Nordisk (Victoza
®
). Gelatin (Type A, from porcine 
skin), Dulbecco’s minimum essential medium (DMEM) and DMEM/F12 (Nutrient mixture F-12) 
were also acquired from Sigma-Aldrich. Phosphate buffered saline (PBS, pH 7.4) was freshly 
prepared. Any mention of other chemicals and their respective origin are indicated along the 
text.  
 
2.1.1 Preparation of PLA and PLA/Liraglutide solutions 
PLA was first dissolved in chloroform; the solution was stirred for up to 20 h, at room 
temperature. After that, 10 µM of Liraglutide was homogenized in DMF, this solution was 
incorporated into the PLA solution to a final PLA concentration of 10% (w/v) and the resulting 
mixture (3:1 Chloroform:DMF) was stirred for 1 h. The whole procedure was performed in a 
hermetically sealed container at 24 ºC ± 2 ºC; relativity humidity at 40 ± 10%. 




The prepared solution (previously described in the 2.1.1 section) was sucked into 
a glass syringe (BD Yale™), and fixed horizontally in a syringe infusion pump (KDS-100, 
KdScientific). Subsequently, the positive electrode was connected to the needle 
(Inbras®, 0.7 mm in diameter) attached to the syringe and the negative, to a metallic 
apparatus (10 cm x 10 cm x 0.3 cm) covered with aluminium foil as a fiber collector (10 





, 15kV as positive voltage). Electrospinning was carried out for up to 
1 h at 24 ± 2 ºC and relative 'humidity at 40 ± 10 % (flow rate of 0.7 mL h
-1
). Electrospun 
fibers were collected on the aluminium foil, dried in the vacuum for 3 h and stocked at 
4ºC.  
 
2.1.3 In situ encapsulation (biodevice assembly) 
In situ encapsulation was performed in order to modify the surface of the 
PLA/Liraglutide fibers, producing our biodevice. For this, gelatin was dissolved in sterile PBS 
(10% w/v). The solution was stirred for 2 h in a hermetically sealed container at 35 ºC to 
complete dissolution. After that, at room temperature, 0,2 µM of commercial Liraglutide was 
added to the gelatin solution and kept under agitation for 30 min in a closed system with 
controlled atmosphere. The solution was placed in a Petri dish and the PLA/Liraglutide fibers 
produced (previously described in the 2.1.2 section) were removed from the aluminium foil and 
immersed into the gelatin solution (10% w/v). Following that, the biodevice was removed and 




2.2.1 Scanning electron microscopy (SEM) and field-emission scanning electron 
microscopy (FE-SEM) 
 The fibers and biodevice morphologies were characterized by both FE-SEM (Lyra3 XM, 
Tescan
®
) and SEM (Zeiss EVO MA-10). All samples were coated with a thin layer of gold, using 
a sputter-coat system (K 550X, EmiTech) before analysis.  
 
2.2.2 Fiber Diameter 
The average fiber diameters were measured from the analysis of the SEM micrographs 
(n=100 fibers), using ImageJ
®
 software. The data were expressed as media and ± standard 
deviation. 
 
2.2.3 Attenuated Total Reflectance Fourier Transform infrared (ATR-FTIR) 
 
 
The structure of electrospun PLA and PLA/Liraglutide fibers and Liraglutide was 
obtained on an ATR-FTIR spectrophotometer (Spotlight-400, Perkin Elmer FTIR Imaging 
System), in the range from 4000 to 0 cm
−1
, in transmittance mode. 
 
2.2.4 Wettability (contact angle measurements) 
The wetting of aqueous drops on the PLA fibers and biodevice surfaces were 
characterized using a goniometer (EasyDrop DAS 100S, KRUSS). The measurements were 
based on the sessile-drop method using aqueous drops at a volume of 2 μL placed on a 
substrate. Briefly, images of a single drop of deionized (DI) water deposited on PLA fibers and 
on the biodevice were periodically acquired (every 5 minutes), by a custom setup with a CCD 
camera. The first contact angle was measured 15 s after the drop casting to ensure that the 
droplet reached its equilibrium position. In order to estimate the contact angle values, a plugin
 
for the open-source software ImageJ
®
 was exploited 
22
. All measurements were carried out in a 
controlled humidified atmosphere (50 ± 10%). After the wettability assay, it was possible to 
reach the time it took to the materials completely absorb the DI water drop.  
 
2.2.5 Zeta Potential 
The zeta potential is a key indicator of a molecule stability dispersed in a solution. Zeta 
potential was analyzed by dynamic light scattering (Delsa™ Nano Beckman Coulter, USA). Zeta 
potential of the peptide was measured by diluting Liraglutide in a DMF solution.  
 
2.3 Liraglutide release in vitro 
 
The in vitro release of Liraglutide was evaluated by soaking the PLA/Liraglutide fibers 
(~30 mg) into 30 mL of sterile PBS (pH 7.4) in a hermetically sealed container, which was kept 
under constant agitation, in a shaker at 37 °C and 75 rpm. At regular time intervals (1, 2, 3, 6, 
12, 24, 48, 72, 120, 168, 240, 360, 480, 600, 720 and 1440 h; 0 to 60 days in total), 3 mL of 
sample were withdrawn and stored at −20 °C until analysis. Then, to the remaining released 
solution, 3mL of pre-warmed PBS was added after each interval, to maintain the constant 
volume 
23-25
.  Subsequently, the amount of Liraglutide in the collected samples was quantified 
 
 
by UV-visible spectroscopy (DeNovix DS-11), at an absorbance wavelength of 280 nm. PLA 
fibers (~30mg) without Liraglutide were maintained under the same conditions and the collected 
periodic solutions were taken to zero the instrument before each regular time interval of 
analysis. 
The amount of Liraglutide present in the release buffer was determined by converting  the 
detected UV absorbance to its concentration according to the calibration curve of known 
concentrations of Liraglutide in the same buffer (PBS). All solutions were freshly prepared and 
the absorbance was immediately measured. The cumulative percentage of the released 
Liraglutide was calculated. The assay was performed in triplicate; data are represented as 
mean ± standard deviation.  
 
2.4 Therapy with the produced materials  
 
2.4.1 Cell culture 
SH-SY5Y cells (a human neuroblastoma cell line) was kindly provided by the Laboratory 
of Chemical Biochemistry (Biochemistry Department, Universidade Federal do Rio Grande do 
Sul, BRA) and maintained in DMEM/F12 (1:1), supplemented with 10% FBS and a 1% 
antibiotic-antimicotic solution at 37C in a humidified incubator in an atmosphere of 5% CO2. 
These cells were used to determine the neurprotective influence of the biodevice after an H2O2 
oxidative stress challenge indicative of AD. 
L929 cells (murine fibroblast, derived from L line; ATCC®CCL-1TM), acquired from the 
Bank of Cells of Rio de Janeiro - BCRJ (BCRJ: 0188, lot 001 158) were used in order to 
evaluate cell adhesion on the biodevice and provide general cytotoxicity data. This cell line was 
cultured using DMEM supplemented with 10% FBS and a 1% antibiotic-antimitotic solution and 
was further maintained at 37 °C in an atmosphere of 5% CO2.  
  
 2.4.2 Therapy  
In order to sterilize the materials (cut with dimensions of 1cm x 1cm), they were quickly 
immersed in 70% ethanol, followed by sterile PBS and DMEM/F12 medium before being placed 
in contact with cells.  
 
 
For each of the following assays, SH-SY5Y cells were seeded and plated at the density 
of 6 x 10
4
 cells/well and then were incubated in a 5% CO2 humidified atmosphere, at 37 ºC. 
Cells attained 50-70% confluence within 24 h. Then, cells were serum starved for 12 h in 0.5% 
FBS DMEM/F12 medium 
26
. Subsequently, cells were incubated with the materials for 24 h; 
after that, materials and medium were removed and cells were stressed by exposed to 5µM 
H2O2 for 1 h.  
 
2.5 Therapeutic effects of the produced materials 
 
2.5.1 Cell viability  
SH-SY5Y cells viability was evaluated by the Trypan blue exclusion assay. Materials 
were incubated within the plated cells (previously described in the 2.4.2 section) and viability 
was evaluated on days 1, 2 and 7.  After H2O2 incubation, cells were washed with PBS, 
trypsinized, centrifuged and the pellet was resuspended in DMEM/F12 medium. Cells were 
stained with a Trypan blue dye (0.4% diluted in PBS, Sigma-Aldrich) for 5 min. Then, viable 




2.5.2 Mitochondrial reactive oxygen species (ROS) detection 
For ROS fluorescence intensity detection, therapy (previously described in section 
2.4.2) was normally performed for 24 h; however, in order to achieve an optimal fluorescence 
reading, cells were seeded in optical-bottom microplates (Nunc, Thermo Scientific™). This plate 
had a polystyrene black structure with a film at the bottom of the plate, facilitating a 
fluorescence reading. 
After H2O2 incubation, cells were exposed to 5 μM MitoSOX Red (Invitrogen/Molecular 
probes) for 10 min and washed with PBS. Fluorescence intensity was measured using a 
fluorescence reader (BioTek®). MitoSOX Red was excited at 485 ± 40 nm and emission was 
collected at 590 ± 20 nm. 
In parallel, for the immunofluorescence imaging of MitoSOX Red, therapy (previously 
described in section 2.4.2) was normally performed. Afterwards, cells were labelled with 
MitoSOX Red, as previously described and the nuclei were stained using DAPI. 
 
 
Photomicrographs were acquired using a fluorescence microscope (Leica Epifluorescence 
Microscope DMLB with a camera to capture pictures; model Leica DFC310FX).  
 
2.6 Cell adhesion on the biodevice 
The L929 cell line was used to verify cellular adhesion on the materials. For this, L929 
cells (6 x 10
4 
cells/well) were cultivated on the materials (cut to dimensions of 1cm x 1cm), for 
24 h, in a 5% CO2 humidified atmosphere, at 37ºC. After that, L929 cells were fixed with 4% 
paraformaldehyde/2.5% glutaraldehyde (Sigma-Aldrich) solution for 10 min. The adherent cells 
were dehydrated using the following sequences of acetone/DI mixture (10 min each): 10, 30, 
50, 70, 90 and 100% (v/v). Then, samples were immersed in 100% 
acetone/hexamethyldisilazane (HMDS) (Sigma-Aldrich ≥99%) (1:1) and finally in HMDS, both 
for 10 min. All procedures were performed at room temperature. The materials were dried at 
room temperature, sputter-coated with a thin layer of gold (~10 nm) and subjected for SEM 
analysis. To quantify cell spreading area, micrographs were converted to black-and-white 
images using ImageJ software and the area of each cell was then measured. 
 
2.7 Statistical analysis 
 
Results were expressed as the mean ± standard deviation. Statistical analysis were 
performed by the unpaired Student’s t test and one-way ANOVA, followed by a Bonferroni post 
hoc, for multiple comparison, using the Prism 5.0 (GraphPad Inc. USA); p < 0.05 was 
considered to be statistically significant.  
 
3 Results and Discussion 
In this study, a novel ultrathin PLA/Liraglutide/gelatin biodevice was synthesized. It was 
characterized and experimentally tested for AD therapy in vitro, enhancing Liraglutide long-
sustained release. This achievement has great potential, since AD is a chronic disease and, 
 
 
currently, all symptomatic treatments are intrinsically long-term and dependant on daily 
medication. 
Liraglutide was loaded into the PLA fibers by using a simple mixture, both peptide and 
polymer were electrospun together, a very important asset for drug delivery systems and the 
generation of a three dimensional functional biological structures. This drug delivery method 
allows simple diffusion of the peptide, which is characterized by an initial burst release by 




Focusing on releasing drugs in a controlled sustained manner, we encapsulated the 
fibers by introducing a sheath layer of gelatin around them, which also contained Liraglutide, but 
at a lower concentration, in order to control the initial burst release from the fibers. Therefore, 
the capsule created a hydrophilic drug-loaded external layer, exposed on the top of the 
biodevice, which permitted better biological interaction and loaded the correct amount of drug. 
This accomplishment may provide sustained release from the first contact with the organic fluid, 
once the gelatin prevents the films from disintegration or shear forces under physiological 
conditions 
28. 
Besides, the surface modification of our PLA/Liraglutide fibers using the gelatin capsule 
was a method to introduce better biofunctionality to the material, making it more biochemically 
and structurally similar to the tissue 
29
. 
Fig. 1 shows SEM and FE-SEM micrographs of the evaluated materials (PLA and 
PLA/Liraglutide fibers and the biodevice). Fig. 1A demonstrates that PLA fibers did not present 
beads or defects. Clearly, there was a distinct rough surface in PLA/Liraglutide fibers (Fig. 1B). 
From this, it can be morphologically assumed that Liraglutide was successfully incorporated into 
PLA fibers. Fig 1C exhibits the biodevice morphology, gelatin capsule can be well observed.  
Fig. 1 also demonstrates histograms of the diameter distribution (n=100). As expected, 
PLA fibers diameter (738.044 ± 74.74 nm) slightly increased once Liraglutide was incorporated 
into them (1055.75 ± 131.69 nm)  and increased even more with gelatin capsules (1389.56 ± 
267.34 nm), which in turn may be responsible for their more heterogeneous diameter (Fig 





Fig. 1: SEM and FE-SEM micrographs of (A) PLA fibers, (B) PLA/Liraglutide fibers and the (C) 
Biodevice. Histograms of the PLA diameter distribution collected from SEM micrographs from 
(A1) PLA fibers, (B1) PLA/Liraglutide fibers and the (C1) Biodevice; (n=100 fibers for all 
groups).  
 
To further identify the chemical structure of the material, FTIR spectra were recorded in 
the range from 4000 to 0 cm
−1
 (Fig. 2A). Clearly, it was observed that Liraglutide is present 
within the polymeric chains of the PLA/Liraglutide fibers (Fig. 2A). We can assume that due to 
the presence of carboxylic acid C=O symmetric stretching vibrations peaks of Liraglutide, mainly 
10µm 
10µm 10 µm 
 
 
represented at 1632 cm
-1
, (characteristically for amino acid chains 
30-32





. Both were observed in Liraglutide and PLA/Liraglutide fibers spectra. 
The data support that Liraglutide was well-loaded and was kept intact within the fibers, since the 
same absorption bands are shown for both the Liraglutide and PLA/Liraglutide scaffolds. 
The successful sustained drug release from polymeric fibers has been considered an 
important parameter for investigation 
4
. It is known that poly (L-lactic acid)/poly (lactic-co-glycolic 
acid) (PLLA/PLGA) electrosprayed particles are able to release drugs for 30 days 
35
. Liraglutide 
release behavior from PLA/Liraglutide fibers was investigated at pH 7.4 (Fig. 2B). We observed 
that our PLA/Liraglutide fibers were able to release Liraglutide for over 60 days.  
As shown and expected (Fig. 2B), our release profile has two main characteristics: a 
burst release stage for the first week, especially for the first 24h followed by a slow, well-
controlled and linear release (from 7 to 60 days respectively), maintained at ~100nM per day 
(~1% of Liraglutide content in the fibers released per day), which is ideal for our in vitro model 
26
. The burst release of a high amount of loaded Liraglutide from the fibers within the first week 
was mainly due to the diffusion of Liraglutide dispersing around the fibers. The gelatin capsule 
was able to improve this 7 days burst release; however, although Liraglutide released from the 
biodevice could not be quantified by a UV spectrophotometer, due to the gelatin density and its 
absorption band, we confirmed gelatin efficiency by different surface wettability measurements 
(Fig. 2C).  
Fig. 2C and D indicated the wettability scheme of PLA fibers and the biodevice, 
respectively, showing snapshots and contact angle measurements every 5 min until the time it 
took to completely absorb a drop of DI water into the samples. The contact angle of droplets 
provides a measure of wettability of the substrate on which they sit, indicating whether the 
wetting of the substrate is increased or not 
36
. The initial contact angle of PLA fibers was 
156.467º (±1.457º) while for the biodevice, the angle was much lower (49.9º ±0.959º). The DI 
water drop was fully absorbed by PLA fibers after 60 min, while biodevices took no more than 
30 min. These differences in wettability indicated that hydrophilicity increased once fibers were 
encapsulated with gelatin. Based on this result, it is suggested that the in situ gelatin capsule 
 
 




Zeta potential plays an important role in overall drug physical stability. Zeta potential 
indicated that, once in suspension, Liraglutide interacts well with the fluid electrospinning 
solution (-19.01mV), this measurement corroborates with the one described by Kaasalainen et 
al. (2012) 
38
, indicating that the peptide may be biologically stable and functional.  
Encapsulation efficiency and burst release are two related parameters showing how 
effectively the drug is captured and released within the polymer  
39
. The capsule was able to 
enhance drug-encapsulation efficiency, better controlling the release of the drug and reducing 
the burst release in the first week.  
 
Fig. 2: Characterization of the produced materials. (A) ATR-FTIR spectra of: PLA/Liraglutide 
fibers; PLA fibers and Liraglutide, respectively. * and ** refers to the peptide bands, 1632 and 
3410 cm
-1
 wavenumber, respectively. (B) Cumulative percentage in vitro release of Liraglutide 
 
 
from PLA/Liraglutide fibers immersed in PBS at pH 7.4. (C and D) Contact angle and wettability 
scheme of the PLA fibers and biodevice, respectively. 
 
Fig. 3 shows cell viability measured using the Trypan blue exclusion assay up to 7 days. 
All materials maintained higher cell viability than the stressed group in all periods of incubation. 
H2O2 induced stress represents the stress that neurons are exposed to in AD. 
Sharma et al (2014) 
26
 described that Liraglutide has neuroprotective effects on SH-
SY5Y viability when oxidatively stressed, reducing an inflammatory response 
40
. Our results 
corroborate with theirs in that the amount of cells only stressed with H2O2 was much lower. 
However, once cells were pre-treated with the materials and then stressed, it was observed that 
PLA fibers containing Liraglutide and the biodevice were not cytotoxic and significantly 
increased SH-SY5Y viability (p<0.001), 24 and 48h after treatment. Curiously, PLA not 
containing Liraglutide also maintained SH-SY5Y viability, especially (Do you mean ‘perhaps’?) 
because the L-lactate released by PLA fibers degradation is required to maintain the 
metabolism and self-renewal of neurogenic progenitors 
41
; generates angiogenesis 
42
 facilitating 
neurogenesis and vascularization of a damaged brain 
8
. After 7 days, the percentage of 
stressed cells was much lower, but cells treated with the biodevice showed a considerable 
higher viability, indicating that the release of Liraglutide was highly controlled and the biodevice 
was efficiently treating the cells, improving their viability.  




Fig. 3: Viability of SH-SY5Y cells pre-treated with the developed materials and stressed with 
H2O2. (A) Cells were pre-treated with PLA fibers; PLA/Liraglutide fibers, biodevice and materials 
were allowed to be in contact with the cells for 1 day and H2O2 stress was performed after that. 
(B and C) Same groups were evaluated, but the materials were kept in contact with the cells for 
2 and 7 days, respectively, and H2O2 stress was performed every 24h. (D) Comparison between 




p<0.001; ns non-significant vs control). 
 
We examined mitochondrial ROS levels of SH-SY5Y cells with MitoSOX Red 
fluorescent, which is a live-cell permeant probe that selectively targets mitochondria and 
exhibits bright red fluorescence when oxidized by superoxides 
43
. It was observed that the 
pre-treatment with Liraglutide and biodevice significantly reduced superoxide generation in 
the mitochondria of SH-SY5Y stressed with 5µM H2O2 (Fig. 4). (Non-significant for Liraglutide 
and p<0.001 for the biodevice). All treated groups showed ROS reduction. In imaging, MitoSOx 
migrated to the nucleus once it was oxidised. Mitochondria are the major source of intracellular 
ROS 
44, 45
. It is well established that mitochondrial dysfunction and oxidative stress play an 
important role in AD, considered to be an early event in this dementia 
46, 47
. The oxidative 
stress leads to increased ROS production and precedes the onset of AD development 
48
, 
supporting a causative importance of mitochondrial dysfunction in AD. 
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Fig. 4: Reduced mitochondrial ROS levels in SH-SY5Y cells pre-treated with Liraglutide or the 
biodevice followed by H2O2 stress. (A-D) Fluorescence microscopy: (A) Control; (B) 5µM H2O2; 
(C) 100nM Liraglutide; and the (D) Biodevice. (E) Fluorescence intensity of the same groups. 
White arrow shows the higher intensity of ROS in the stressed group, compared to the other 
ones (
***
p<0.001 and ns non-significant vs control). 
 
L929 cell adhesion to the materials was evaluated in order to verify in vitro material 
implant potential. We also investigated if the gelatin capsule facilitated cellular adhesion (Fig. 5). 
Fig. 5A shows that the L929 cells efficiently adhered to PLA fibers after 24 h of incubation (cell 
spreading area 10362 ± 2735 µm
2
). However, due to their high hydrophobicity, cells were 
neither well attached nor diffused as much as observed in Fig. 5B and 5C. In Fig. 5B, it is 
notable that cells interacted with PLA/Liraglutide fibers (cell spreading area 18976 ± 3613 µm
2
). 
In Fig. 5C, a great interaction between the biodevice and cells was observed (cell area 26408 ± 
5081 µm
2
), ensuring that this material will be well-fixed once implanted and not induce toxicity to 
fibroblasts; Fig. 5C also demonstrated that gelatin coating was rough. Fig. 5D represents L929 
cell spreading area on the materials, which ensures that wettability certainly influences cell 










Fig. 5: Material degradation and L929 cell attachment and spreading area after 24h of 
incubation. (A) PLA fibers; (B) PLA/Liraglutide fibers; and the (C) Biodevice. Images in the left 
 
 
indicate material degradation, while images in the right show L929 cells adherent to the 
materials. Cell spreading area on materials. The white arrow shows the fiber surface after 
Liraglutide incorporation; the yellow arrow indicate degraded gelatin and the red arrows shows 
the great strong interaction between the cell and the biodevice. (Where is the colour in the 
images coming from?) 
 
It is well stablished that hydrophobicity of electrospun fibers is not good for cell 
attachment and proliferation, so fiber surface modification which adds hydrophilicity to the 
material is favorable for cellular interactions 
2, 49
. Furthermore, introducing a hydrophilic shell to 
a hydrophobic polymer produces a highly water-swellable fiber, facilitating drug delivery 
systems 
4
. Fibroblasts are able to produce fibers and amorphous substances, contributing to the 
healing process and implant reception. They are activated by chemical mediators, which are 
also responsible for avoiding inflammatory processes and, facilitating implant stabilization 
50
. 
The implant, in a short period, is involved (do you mean overgrown?) by fibroblasts and 
sanguineous blood capillaries in order to maintain stabilized conditions; another group of 
fibroblasts will then seal the lesion 
51
.  
It is believed that the electrospinning technique employed here brings nano and ultrathin 
materials closer to clinical applications 
52
; and with our results, it is expected that the developed 
biodevice may provide a new concept of great therapeutic potential for AD. Clearly, gelatin 
capsules conferred a great approachimportant properties to our drug delivery system, 
increasing hydrophilicity, facilitating cell adhesion and spreading.  Moreover,  the capsule 





In this study, we propose the concept design of a bioresorbable ultrathin biodevice for 
the sustained release of Liraglutide as a potential therapy focusing onfor AD. The developed 





conformation (what do you mean by conformation?) and provides a sustained release of the 
drug for up to 60 days. 
Promisingly, our results open up exciting perspectives in the design of implantable 
devices for AD drug delivery, which could also provide great novel approaches for other chronic 
disease therapies too. Our biodevice allows Liraglutide to easily homogenization homogenize 
within a PLA solution. Liraglutide incorporation into the fibers was confirmed by FTIR and 
peptide integrity was observed by zeta potential. The potential of our biodevice was confirmed 
by wettability measurements, and once fibers were encapsulated with gelatin such wettability 
increased, which permitted better biological and in vitro interactions, increasing neuroblastoma 
neuroprotective viability, reducing ROS production indicative of AD progression. The strategical 
(why is it strategical?) biodevice provides a guideline to the development of an implantable 
material that may represent an important impact for AD therapy. 
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